Screener
Baxter International BAX Infusion Therapies & Technologies — Net Sales
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Baxter International in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Baxter International’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:50 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-028962
| (in millions) | Three Months Ended March 31, 2026 / U.S. | Three Months Ended March 31, 2026 / International | Three Months Ended March 31, 2026 / Total | Three Months Ended March 31, 2025 / U.S. | Three Months Ended March 31, 2025 / International | Three Months Ended March 31, 2025 / Total |
|---|---|---|---|---|---|---|
| Infusion Therapies & Technologies | $526 | $455 | $981 | $584 | $410 | $994 |
| Advanced Surgery | 165 | 139 | 304 | 145 | 123 | 268 |
| Medical Products & Therapies | 691 | 594 | 1,285 | 729 | 533 | 1,262 |
| Care & Connectivity Solutions | 315 | 120 | 435 | 316 | 111 | 427 |
| Front Line Care | 198 | 72 | 270 | 202 | 75 | 277 |
| Healthcare Systems & Technologies | 513 | 192 | 705 | 518 | 186 | 704 |
| Injectables & Anesthesia | 180 | 121 | 301 | 195 | 140 | 335 |
| Drug Compounding | — | 320 | 320 | — | 246 | 246 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Baxter International's infusion therapies & technologies — net sales?
- Baxter International (BAX) reported infusion therapies & technologies — net sales of $981M in Q1 2026.
- How has Baxter International's infusion therapies & technologies — net sales changed year-over-year?
- Baxter International's infusion therapies & technologies — net sales decreased by 1.3% year-over-year, from $994M to $981M.
- What is the long-term trend for Baxter International's infusion therapies & technologies — net sales?
- Over 3 years (2021 to 2025), Baxter International's infusion therapies & technologies — net sales has grown at a 2.2% compound annual growth rate (CAGR), from $3.84B to $4.1B.
- What does infusion therapies & technologies — net sales mean?
- This metric represents the total revenue generated from the sale of infusion pumps, administration sets, and related software and services within the specified business segment. It reflects the company's ability to monetize its portfolio of medical devices used for the controlled delivery of fluids, medications, and nutrients to patients in clinical settings. Growth in this area is driven by product innovation, market penetration of connected infusion systems, and recurring revenue from consumables.
Ask your AI about Baxter International's infusion therapies & technologies — net sales.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude